{"DataElement":{"publicId":"5644566","version":"1","preferredName":"Testicular Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group Stage","preferredDefinition":"Stage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for testicular carcinoma.","longName":"5644541v1.0:5644499v1.0","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"5644541","version":"1","preferredName":"Malignant Testicular Germ Cell Tumor Stage Grouping","preferredDefinition":"A malignant tumor predominantly affecting young men and often associated with cryptorchidism.  Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.","longName":"2986052v1.0:2230143v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2986052","version":"1","preferredName":"Malignant Testicular Germ Cell Tumor","preferredDefinition":"A malignant tumor predominantly affecting young men and often associated with cryptorchidism.  Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor. -- 2004","longName":"C9063","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Testicular Germ Cell Tumor","conceptCode":"C9063","definition":"A malignant germ cell tumor that arises from the testis. It predominantly affects young men. Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D112249-82D8-E0FD-E040-BB89AD432FCB","latestVersionIndicator":"Yes","beginDate":"2010-01-13","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-01-13","modifiedBy":"ONEDATA","dateModified":"2010-01-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2230143","version":"1","preferredName":"Stage Grouping","preferredDefinition":"Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR)","longName":"C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F752037A-4CC2-36A8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-18","modifiedBy":"ONEDATA","dateModified":"2005-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Application","id":"47667353-FAF7-6F63-E053-F662850A2962","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"COOPERM","dateModified":"2017-01-31","changeDescription":"Created for CRF standard harmonization. mc 1/31/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5644499","version":"1","preferredName":"Testicular Cancer American Joint Committee on Cancer Edition 7 Group Stage","preferredDefinition":"A malignant tumor predominantly affecting young men and often associated with cryptorchidism.  Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor._A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage._The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"5644499v1.0","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"13","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Stage unknown","valueDescription":"Stage Unknown","ValueMeaning":{"publicId":"3357508","version":"1","preferredName":"Stage Unknown","longName":"3357508","preferredDefinition":"A finding indicating that the extent of organ/tissue involvement by a malignant neoplasm is not reported or not assessed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Unknown","conceptCode":"C92207","definition":"The extent of organ/tissue involvement by a malignant neoplasm is not reported or not assessed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6D76279-6263-2CA8-E040-BB89AD434A54","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"476602A3-C0D4-07FC-E053-F662850A260D","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"ONEDATA","dateModified":"2017-01-31","deletedIndicator":"No"},{"value":"IIIC","valueDescription":"Stage IIIC Testicular Cancer","ValueMeaning":{"publicId":"5644501","version":"1","preferredName":"Stage IIIC Testicular Cancer","longName":"5644501","preferredDefinition":"Stage IIIC includes: (Any pT/TX, N1-3, M0, S3); (Any pT/TX, Any N, M1a, S3); (Any pT/TX, Any N, M1b, Any S).  N1: Metastasis with a lymph node mass 2 cm or less in greatest dimension; or multiple lymph nodes, none more than 2cm in greatest dimension.  N2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension.  N3: Metastasis with a lymph node mass more than 5 cm in greatest dimension. M0: No distant metastasis. M1a: Non-regional nodal or pulmonary metastasis.  M1b: Distant metastasis other than to non-regional lymph nodes and lung.  S3: LDH more than 10 x N (N indicates the upper limit of normal for the LDH assay) or hCG more than 50,000 or AFP more than 10,000. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIC Testicular Cancer AJCC v6 and v7","conceptCode":"C6367","definition":"Stage IIIC includes: (Any pT/TX, N1-3, M0, S3); (Any pT/TX, Any N, M1a, S3); (Any pT/TX, Any N, M1b, Any S).  N1: Metastasis with a lymph node mass 2 cm or less in greatest dimension; or multiple lymph nodes, none more than 2cm in greatest dimension.  N2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension.  N3: Metastasis with a lymph node mass more than 5 cm in greatest dimension. M0: No distant metastasis. M1a: Non-regional nodal or pulmonary metastasis.  M1b: Distant metastasis other than to non-regional lymph nodes and lung.  S3: LDH more than 10 x N (N indicates the upper limit of normal for the LDH assay) or hCG more than 50,000 or AFP more than 10,000. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476602A3-C0E1-07FC-E053-F662850A260D","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"476602A3-C0FA-07FC-E053-F662850A260D","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"ONEDATA","dateModified":"2017-01-31","deletedIndicator":"No"},{"value":"IIIB","valueDescription":"Stage IIIB Testicular Cancer","ValueMeaning":{"publicId":"5644503","version":"1","preferredName":"Stage IIIB Testicular Cancer","longName":"5644503","preferredDefinition":"Stage IIIB includes: (Any pT/TX, N1-3, M0, S2); (Any pT/TX, Any N, M1a, S2).  N1: Metastasis with a lymph node mass 2 cm or less in greatest dimension; or multiple lymph nodes, none more than 2cm in greatest dimension.  N2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension.  N3: Metastasis with a lymph node mass more than 5 cm in greatest dimension. M0: No distant metastasis. M1a: Non-regional nodal or pulmonary metastasis. S2: LDH 1.5-10 x N (N indicates the upper limit of normal for the LDH assay) or hCG 5,000-50,000 or AFP 1,000-10,000.  (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIB Testicular Cancer AJCC v6 and v7","conceptCode":"C6368","definition":"Stage IIIB includes: (Any pT/TX, N1-3, M0, S2); (Any pT/TX, Any N, M1a, S2).  N1: Metastasis with a lymph node mass 2 cm or less in greatest dimension; or multiple lymph nodes, none more than 2cm in greatest dimension.  N2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension.  N3: Metastasis with a lymph node mass more than 5 cm in greatest dimension. M0: No distant metastasis. M1a: Non-regional nodal or pulmonary metastasis. S2: LDH 1.5-10 x N (N indicates the upper limit of normal for the LDH assay) or hCG 5,000-50,000 or AFP 1,000-10,000.  (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476602A3-C107-07FC-E053-F662850A260D","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"476602A3-C120-07FC-E053-F662850A260D","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"ONEDATA","dateModified":"2017-01-31","deletedIndicator":"No"},{"value":"IIIA","valueDescription":"Stage IIIA Testicular Cancer","ValueMeaning":{"publicId":"5644505","version":"1","preferredName":"Stage IIIA Testicular Cancer","longName":"5644505","preferredDefinition":"Stage IIIA includes: (Any pT/TX, Any N, M1a, S0); (Any pT/TX, Any N, M1a, S1).  M1a: Non-regional nodal or pulmonary metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N (N indicates the upper limit of normal for the LDH assay) and hCG less than 5,000 and AFP less than 1,000.  (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIIA Testicular Cancer AJCC v6 and v7","conceptCode":"C6369","definition":"Stage IIIA includes: (Any pT/TX, Any N, M1a, S0); (Any pT/TX, Any N, M1a, S1).  M1a: Non-regional nodal or pulmonary metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N (N indicates the upper limit of normal for the LDH assay) and hCG less than 5,000 and AFP less than 1,000.  (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476602A3-C12D-07FC-E053-F662850A260D","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"476602A3-C146-07FC-E053-F662850A260D","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"ONEDATA","dateModified":"2017-01-31","deletedIndicator":"No"},{"value":"III","valueDescription":"Stage III Testicular Cancer","ValueMeaning":{"publicId":"5644507","version":"1","preferredName":"Stage III Testicular Cancer","longName":"5644507","preferredDefinition":"Stage III is divided into stage IIIA, stage IIIB, and stage IIIC, and is determined after a radical inguinal orchiectomy (surgery to remove the testicle) is done. In stage IIIA, cancer is anywhere within the testicle, spermatic cord, or scrotum; may have spread to one or more lymph nodes in the abdomen; and has spread to distant lymph nodes or to the lungs; tumor marker levels may range from normal to slightly above normal. In stage IIIB, cancer is anywhere within the testicle, spermatic cord, or scrotum; and may have spread to one or more lymph nodes in the abdomen, to distant lymph nodes or to the lungs; the level of one or more tumor markers is moderately above normal. In stage IIIC, cancer is anywhere within the testicle, spermatic cord, or scrotum; and may have spread to one or more lymph nodes in the abdomen, to distant lymph nodes, or to the lungs; the level of one or more tumor markers is high; OR, cancer is anywhere within the testicle, spermatic cord, or scrotum; and may have spread to one or more lymph nodes in the abdomen; and has not spread to distant lymph nodes or the lung but has spread to other parts of the body; tumor marker levels may range from normal to high.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage III Testicular Cancer AJCC v6 and v7","conceptCode":"C9074","definition":"Stage III includes: Any pT/TX, Any N, M1, SX.  M1: Distant metastasis. SX: Marker studies not available or not performed.  (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476602A3-C153-07FC-E053-F662850A260D","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"476602A3-C16C-07FC-E053-F662850A260D","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"ONEDATA","dateModified":"2017-01-31","deletedIndicator":"No"},{"value":"IIC","valueDescription":"Stage IIC Testicular Cancer","ValueMeaning":{"publicId":"5644509","version":"1","preferredName":"Stage IIC Testicular Cancer","longName":"5644509","preferredDefinition":"Stage IIC includes: (Any pT/TX, N3, M0, S0); (Any pT/TX, N3, M0, S1).  pTX: Primary tumor cannot be assessed.  N3: Metastasis with a lymph node mass more than 5 cm in greatest dimension. M0: No distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N (N indicates the upper limit of normal for the LDH assay) and hCG less than 5,000 and AFP less than 1,000.  (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIC Testicular Cancer AJCC v6 and v7","conceptCode":"C6366","definition":"Stage IIC includes: (Any pT/TX, N3, M0, S0); (Any pT/TX, N3, M0, S1).  pTX: Primary tumor cannot be assessed.  N3: Metastasis with a lymph node mass more than 5 cm in greatest dimension. M0: No distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N (N indicates the upper limit of normal for the LDH assay) and hCG less than 5,000 and AFP less than 1,000.  (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476602A3-C179-07FC-E053-F662850A260D","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"476602A3-C192-07FC-E053-F662850A260D","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"ONEDATA","dateModified":"2017-01-31","deletedIndicator":"No"},{"value":"IIB","valueDescription":"Stage IIB Testicular Cancer","ValueMeaning":{"publicId":"5644511","version":"1","preferredName":"Stage IIB Testicular Cancer","longName":"5644511","preferredDefinition":"Stage IIB includes: (Any pT/TX, N2, M0, S0); (Any pT/TX, N2, M0, S1).  pTX: Primary tumor cannot be assessed.  N2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension.  M0: No distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N (N indicates the upper limit of normal for the LDH assay) and hCG less than 5,000 and AFP less than 1,000.  (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIB Testicular Cancer AJCC v6 and v7","conceptCode":"C6365","definition":"Stage IIB includes: (Any pT/TX, N2, M0, S0); (Any pT/TX, N2, M0, S1).  pTX: Primary tumor cannot be assessed.  N2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension.  M0: No distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N (N indicates the upper limit of normal for the LDH assay) and hCG less than 5,000 and AFP less than 1,000.  (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476602A3-C19F-07FC-E053-F662850A260D","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"476602A3-C1B8-07FC-E053-F662850A260D","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"ONEDATA","dateModified":"2017-01-31","deletedIndicator":"No"},{"value":"IIA","valueDescription":"Stage IIA Testicular Cancer","ValueMeaning":{"publicId":"5644513","version":"1","preferredName":"Stage IIA Testicular Cancer","longName":"5644513","preferredDefinition":"Stage IIA includes: (Any pT/TX, N1, M0, S0); (Any pT/TX, N1, M0, S1).  pTX: Primary tumor cannot be assessed.  N1: Metastasis with a lymph node mass 2 cm or less in greatest dimension; or multiple lymph nodes, none more than 2cm in greatest dimension.  M0: No distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N (N indicates the upper limit of normal for the LDH assay) and hCG less than 5,000 and AFP less than 1,000. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IIA Testicular Cancer AJCC v6 and v7","conceptCode":"C6364","definition":"Stage IIA includes: (Any pT/TX, N1, M0, S0); (Any pT/TX, N1, M0, S1).  pTX: Primary tumor cannot be assessed.  N1: Metastasis with a lymph node mass 2 cm or less in greatest dimension; or multiple lymph nodes, none more than 2cm in greatest dimension.  M0: No distant metastasis. S0: Marker study levels within normal limits. S1: LDH less than 1.5 x N (N indicates the upper limit of normal for the LDH assay) and hCG less than 5,000 and AFP less than 1,000. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476602A3-C1C5-07FC-E053-F662850A260D","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"476602A3-C1DE-07FC-E053-F662850A260D","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"ONEDATA","dateModified":"2017-01-31","deletedIndicator":"No"},{"value":"II","valueDescription":"Stage II Testicular Cancer","ValueMeaning":{"publicId":"5644515","version":"1","preferredName":"Stage II Testicular Cancer","longName":"5644515","preferredDefinition":"Stage II includes: Any pT/TX, N1-3, M0, SX.  pTX: Primary tumor cannot be assessed.  N1: Metastasis with a lymph node mass 2 cm or less in greatest dimension; or multiple lymph nodes, none more than 2cm in greatest dimension.  N2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension.  N3: Metastasis with a lymph node mass more than 5 cm in greatest dimension. M0: No distant metastasis. SX: Marker studies not available or not performed.  (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage II Testicular Cancer AJCC v6 and v7","conceptCode":"C9073","definition":"Stage II includes: Any pT/TX, N1-3, M0, SX.  pTX: Primary tumor cannot be assessed.  N1: Metastasis with a lymph node mass 2 cm or less in greatest dimension; or multiple lymph nodes, none more than 2cm in greatest dimension.  N2: Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or multiple lymph nodes, any one mass greater than 2 cm but not more than 5 cm in greatest dimension.  N3: Metastasis with a lymph node mass more than 5 cm in greatest dimension. M0: No distant metastasis. SX: Marker studies not available or not performed.  (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476602A3-C1EB-07FC-E053-F662850A260D","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"476602A3-C204-07FC-E053-F662850A260D","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"ONEDATA","dateModified":"2017-01-31","deletedIndicator":"No"},{"value":"IS","valueDescription":"Stage IS Testicular Cancer","ValueMeaning":{"publicId":"5644517","version":"1","preferredName":"Stage IS Testicular Cancer","longName":"5644517","preferredDefinition":"Stage IS includes: Any pT/TX, N0, M0, S1-3.  pTX: Primary tumor cannot be assessed.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  S1: LDH less than 1.5 x N (N indicates the upper limit of normal for the LDH assay) and hCG less than 5,000 and AFP less than 1,000.  S2: LDH 1.5-10 x N or hCG 5,000-50,000 or AFP 1,000-10,000.  S3: LDH more than 10 x N or hCG more than 50,000 or AFP more than 10,000. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IS Testicular Cancer AJCC v6 and v7","conceptCode":"C6363","definition":"Stage IS includes: Any pT/TX, N0, M0, S1-3.  pTX: Primary tumor cannot be assessed.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  S1: LDH less than 1.5 x N (N indicates the upper limit of normal for the LDH assay) and hCG less than 5,000 and AFP less than 1,000.  S2: LDH 1.5-10 x N or hCG 5,000-50,000 or AFP 1,000-10,000.  S3: LDH more than 10 x N or hCG more than 50,000 or AFP more than 10,000. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476602A3-C211-07FC-E053-F662850A260D","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"476602A3-C22A-07FC-E053-F662850A260D","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"ONEDATA","dateModified":"2017-01-31","deletedIndicator":"No"},{"value":"IB","valueDescription":"Stage IB Testicular Cancer","ValueMeaning":{"publicId":"5644519","version":"1","preferredName":"Stage IB Testicular Cancer","longName":"5644519","preferredDefinition":"Stage IB includes: (pT2, N0, M0, S0); (pT3, N0, M0, S0); (pT4, N0, M0, S0).  pT2: Tumor limited to the testis and epididymis with vascular/lymphatic invasion, or tumor extending through the tunica albuginea with involvement of the tunica vaginalis.  pT3: Tumor invades the spermatic cord with or without vascular/lymphatic invasion.  pT4: Tumor invades the scrotum with or without vascular/lymphatic invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  S0: Marker study levels within normal limits. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IB Testicular Cancer AJCC v6 and v7","conceptCode":"C6362","definition":"Stage IB includes: (pT2, N0, M0, S0); (pT3, N0, M0, S0); (pT4, N0, M0, S0).  pT2: Tumor limited to the testis and epididymis with vascular/lymphatic invasion, or tumor extending through the tunica albuginea with involvement of the tunica vaginalis.  pT3: Tumor invades the spermatic cord with or without vascular/lymphatic invasion.  pT4: Tumor invades the scrotum with or without vascular/lymphatic invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  S0: Marker study levels within normal limits. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476602A3-C237-07FC-E053-F662850A260D","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"476602A3-C250-07FC-E053-F662850A260D","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"ONEDATA","dateModified":"2017-01-31","deletedIndicator":"No"},{"value":"IA","valueDescription":"Stage IA Testicular Cancer","ValueMeaning":{"publicId":"5644521","version":"1","preferredName":"Stage IA Testicular Cancer","longName":"5644521","preferredDefinition":"Stage IA includes: pT1, N0, M0, S0.  pT1: Tumor limited to the testis and epididymis without vascular/lymphatic invasion; tumor may invade into the tunica albuginea but not the tunica vaginalis.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  S0: Marker study levels within normal limits. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IA Testicular Cancer AJCC v6 and v7","conceptCode":"C6361","definition":"Stage IA includes: pT1, N0, M0, S0.  pT1: Tumor limited to the testis and epididymis without vascular/lymphatic invasion; tumor may invade into the tunica albuginea but not the tunica vaginalis.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  S0: Marker study levels within normal limits. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476602A3-C25D-07FC-E053-F662850A260D","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"476602A3-C276-07FC-E053-F662850A260D","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"ONEDATA","dateModified":"2017-01-31","deletedIndicator":"No"},{"value":"I","valueDescription":"Stage I Testicular Cancer","ValueMeaning":{"publicId":"5644523","version":"1","preferredName":"Stage I Testicular Cancer","longName":"5644523","preferredDefinition":"Stage I includes: pT1-4, N0, M0, SX.  pT1: Tumor limited to the testis and epididymis without vascular/lymphatic invasion; tumor may invade into the tunica albuginea but not the tunica vaginalis.  pT2: Tumor limited to the testis and epididymis with vascular/lymphatic invasion, or tumor extending through the tunica albuginea with involvement of the tunica vaginalis.  pT3: Tumor invades the spermatic cord with or without vascular/lymphatic invasion.  pT4: Tumor invades the scrotum with or without vascular/lymphatic invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  SX: Marker studies not available or not performed. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage I Testicular Cancer AJCC v6 and v7","conceptCode":"C7901","definition":"Stage I includes: pT1-4, N0, M0, SX.  pT1: Tumor limited to the testis and epididymis without vascular/lymphatic invasion; tumor may invade into the tunica albuginea but not the tunica vaginalis.  pT2: Tumor limited to the testis and epididymis with vascular/lymphatic invasion, or tumor extending through the tunica albuginea with involvement of the tunica vaginalis.  pT3: Tumor invades the spermatic cord with or without vascular/lymphatic invasion.  pT4: Tumor invades the scrotum with or without vascular/lymphatic invasion.  N0: No regional lymph node metastasis.  M0: No distant metastasis.  SX: Marker studies not available or not performed. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476602A3-C283-07FC-E053-F662850A260D","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"476602A3-C29C-07FC-E053-F662850A260D","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"ONEDATA","dateModified":"2017-01-31","deletedIndicator":"No"},{"value":"0","valueDescription":"Stage 0 Testicular Cancer","ValueMeaning":{"publicId":"5644525","version":"1","preferredName":"Stage 0 Testicular Cancer","longName":"5644525","preferredDefinition":"Stage 0 includes: pTis, N0, M0, S0.  pTis: Intratubular germ cell neoplasia (carcinoma in situ).  N0: regional lymph node metastasis.  M0: No distant metastasis.  S0: Marker study levels within normal limits. (AJCC 6th and 7th eds.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0 Testicular Cancer AJCC v6 and v7","conceptCode":"C4523","definition":"Stage 0 includes: pTis, N0, M0, S0.  pTis: Intratubular germ cell neoplasia (carcinoma in situ).  N0: regional lymph node metastasis.  M0: No distant metastasis.  S0: Marker study levels within normal limits. (AJCC 6th and 7th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476602A3-C2A9-07FC-E053-F662850A260D","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"476602A3-C2C2-07FC-E053-F662850A260D","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"ONEDATA","dateModified":"2017-01-31","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5644498","version":"1","preferredName":"Malignant Testicular Germ Cell Tumor American Joint Committee on Cancer Stage Grouping Stage","preferredDefinition":"A malignant tumor predominantly affecting young men and often associated with cryptorchidism.  Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor.:A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.:An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.:The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"C9063:C39315:C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Testicular Germ Cell Tumor","conceptCode":"C9063","definition":"A malignant germ cell tumor that arises from the testis. It predominantly affects young men. Seminoma is the most frequently seen malignant testicular germ cell tumor, followed by embryonal carcinoma and yolk sac tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"American Joint Committee on Cancer","conceptCode":"C39315","definition":"A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"476602A3-C0AB-07FC-E053-F662850A260D","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"ONEDATA","dateModified":"2017-01-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Application","id":"476602A3-C0BC-07FC-E053-F662850A260D","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"COOPERM","dateModified":"2017-01-31","changeDescription":"Created for CRF standard harmonization. mc 1/30/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"3461150","version":"1","longName":"Staging","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3461151","version":"1","longName":"AJCC Edition 7","context":"NCIP"}]},{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"5777529","version":"1","longName":"Testicular","context":"NCI Standards"},{"publicId":"10000596","version":"1","longName":"AJCC Edition 7","context":"NCI Standards"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"AJCC Staging:","url":null,"context":"COG"},{"name":"Disease Stage","type":"Preferred Question Text","description":"Disease Stage","url":null,"context":"NCI Standards"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Preferred Standard","id":"4766C670-7F98-0A29-E053-F662850AD951","latestVersionIndicator":"Yes","beginDate":"2017-01-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-31","modifiedBy":"TAYLORT","dateModified":"2017-04-19","changeDescription":"Created for CRF Harmonization. mc 1/31/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}